OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS
August 03, 2022 12:50 ET
|
Oxeia Biopharmaceuticals Inc.
Phase 2 clinical trial for OXE103 for the treatment of concussion is being conducted at University of Kansas Medical Center, Kansas City, KansasEnrolling highly symptomatic participants within 28 days...